<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04362553</url>
  </required_header>
  <id_info>
    <org_study_id>STU00210413</org_study_id>
    <nct_id>NCT04362553</nct_id>
  </id_info>
  <brief_title>Advanced Wireless, Wearable Sensors for Continuous Hemodynamic Monitoring</brief_title>
  <official_title>Advanced Wireless, Wearable Sensors for Continuous Hemodynamic Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Percent agreement of vital signs monitoring between the experimental sensor and standard of
      care monitoring
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percent agreement with pilot sensor and current standard of vital signs monitoring</measure>
    <time_frame>2 years</time_frame>
    <description>Percent agreement with pilot sensor and current standard of vital signs monitoring</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Congestive Heart Failure</condition>
  <arm_group>
    <arm_group_label>Adults</arm_group_label>
    <description>Adults scheduled to receive a TTE (Trans-esophogeal echocardiogram)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>wearable vital signs sensor</intervention_name>
    <description>vital signs monitoring during standard of care procedures; TTE, swan-ganz catheterization</description>
    <arm_group_label>Adults</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Cardiology patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patient's aged 18-65

          2. Patient's scheduled to undergo a Trans-thoracic Echocardiogram (TTE) in an outpatient
             cardiology clinic or admitted to the Cardiac Care Unit with a swan ganz catheter in
             place for continuous invasive hemodynamic monitoring

        Exclusion Criteria

          1. Patient's with fragile skin or skin conditions that would prevent them from having a
             sensor placed

          2. Patients undergoing exercise or drug induced cardiac stress test

          3. Patients with a visible wound at site of sensor placement 3.4. Patients with
             structural or functional limitations to peripheral blood flow (known upper extremity
             peripheral arterial disease, use of vasopressors etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Knute Martell</last_name>
    <phone>312-503-5944</phone>
    <email>DermSensors@northwestern.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 15, 2020</study_first_submitted>
  <study_first_submitted_qc>April 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2020</study_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Shuai (Steve) Xu</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

